Conformal radiotherapy for hepatocellular carcinoma.
Technical advancements in radiation therapy (RT) have facilitated the safe delivery of conformal, dose-escalated radiation to a wide spectrum of hepatocellular carcinoma (HCC) patients. A variety of doses and RT fractionation schemes have been used, and RT has been used in combination with transarterial chemoembolization (TACE). Compared to untreated historical controls or those treated with TACE alone, outcomes following RT alone or TACE and RT are better. Despite advances in RT delivery, liver toxicity following RT remains a dose-limiting factor, and investigations to better understand the pathophysiology of RT-induced liver toxicity are warranted. For most tumors, RT can provide sustained local control. However, HCC tends to recur within the liver away from the irradiated volume, providing rationale for combining RT with systemic or regional therapies. There is a particular interest in combining RT with anti-VEGF-targeted agents for their independent activity in HCC as well as their radiation sensitization properties. Randomized trials of RT are warranted.
Tse
R V
RV
Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario M5G 2M9, Canada.
Guha
Chandan
C
Dawson
L A
LA
D006528:Carcinoma, Hepatocellular / Q000532:radiotherapy*; D016461:Chemoembolization, Therapeutic; D063193:Heavy Ion Radiotherapy; D006801:Humans; D008099:Liver / Q000528:radiation effects; D008113:Liver Neoplasms / Q000532:radiotherapy*; D061766:Proton Therapy; D016634:Radiosurgery; D020266:Radiotherapy, Conformal / Q000379:methods*; D011522:Protons
D011522:Protons